Endoscopic bariatric therapies

Česká verzia

Authors: Jan Král ; Peter Mačinga ; Drastich P.; Julius Špičák ; Tomáš Hucl
Authors place of work: Klinika hepatogastroenterologie, IKEM, Praha
Published in the journal: Gastroent Hepatol 2021; 75(3): 213-220
Category:
doi: https://doi.org/10.48095/ccgh2021213

Summary

Obesity is a serious global problem. Obesity is associated with a number of serious diseases that reduce the patient‘s quality of life and increase mortality (high blood pressure, dyslipidemia, type 2 diabetes mellitus, cancer and others). The treatment of obesity is a multidisciplinary and complex process that requires the cooperation of the patient. The basis of obesity therapy is a change in lifestyle, another option is pharmacotherapy, but its effectiveness is limited. Surgical therapy is highly effective, however, there is a risk of complications and is indicated in advanced stages of obesity. Endoscopic therapy is less effective than surgical treatment, but associated with less invasiveness and less complications. The main endoscopic methods are based on the principle of volume reduction, restriction of the size or bypass of the stomach or small intestine. The aim of the current publication is to present individual endoscopic methods, including a comparison of their effectiveness and safety.

Keywords:

bariatrics – endoscopy – obesity

Zdroje

1. Yumuk V, Tsigos C, Fried M et al. European guidelines for obesity management in adults. Obes Facts 2015; 8(6): 402–424. doi: 10.1159/ 000442721.

2. World Health Organization. Obesity and overweight. 2020 [online]. Available from: https:/ / www.who.int/ news-room/ fact-sheets/ detail/ obesity-and-overweight.

3. Centers for Disease Control and Prevention. Adult Obesity Facts 2021[online]. Available from: https:/ / www.cdc.gov/ obesity/ data/ adult.html.

4. EUROSTAT. Overweight and obesity – BMI statistics. 2019 [online]. Available from: https:/ / ec.europa.eu/ eurostat/ statistics-explained/ index.php/ Overweight_and_obesity_-_BMI_statistics.

5. Centers for Disease Control and Prevention. Overweight&Obesity. Adult Obesity Facts. 2020 [online]. Available from: https:/ / www.cdc.gov/ obesity/ data/ adult.html.

6. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 2019; 15(5): 288–298. doi: 10.1038/ s41574-019-0176-8.

7. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017; 376(3): 254–266. doi: 10.1056/ NEJMra1514009.

8. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142(4): 711–725. doi: 10.1053/ j.gastro.2012.02.003.

9. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346(8): 591–602. doi: 10.1056/ NEJMra 012586.

10. Šrámková P. Novinky farmakologické léčby obezity. Gastroenterol Hepatol 2018; 72(6): 495–500. doi: 10.14735/ amgh2018495

11. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract 2017. 3(1): 3–14. doi: 10.1002/ osp4.84.

12. Eldar S, Heneghan HM, Brethauer SA et al. Bariatric surgery for treatment of obesity. Int J Obes (Lond) 2011; 35(Suppl 3): S16–S21. doi: 10.1038/ ijo.2011.142.

13. Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Med Clin North Am 2011; 95(5): 1009–1030. doi: 10.1016/ j.mcna.2011.06.010.

14. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403. doi: 10.1056/ NEJMoa012512.

15. Jung SH, Yoon JH, Choi HS et al. Comparative efficacy of bariatric endoscopic procedures in the treatment of morbid obesity: a systematic review and network meta-analysis. Endoscopy 2020; 52(11): 940–954. doi: 10.1055/ a-1149-1862.

16. Neylan CJ, Dempsey DT, Tewksbury CM et al. Endoscopic treatments of obesity: a comprehensive review. Surg Obes Relat Dis 2016; 12(5): 1108–1115. doi: 10.1016/ j.soard.2016.02.006.

17. Nieben OG, Harboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet 1982; 1(8265): 198–199. doi: 10.1016/ s0140-6736(82)90762-0.

18. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 2017; 152(7): 1791–1801. doi: 10.1053/ j.gastro.2017.01.044.

19. Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. Adv Ther 2017; 34(8): 1859–1875. doi: 10.1007/ s12325-017-0562-3.

20. Vargas EJ, Pesta CM, Bali A et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol 2018; 16(7): 1073–1080. doi: 10.1016/ j.cgh.2018.01.046.

21. Fayad L, Cheskin LJ, Adam A et al. Endoscopic sleeve gastroplasty versus intragastric balloon insertion: efficacy, durability, and safety. Endoscopy 2019; 51(6): 532–539. doi: 10.1055/ a-0852-3441.

22. Abu Dayyeh BK, Edmundowicz SA, Jonnalagadda S et al. Endoscopic bariatric therapies. Gastrointest Endosc 2015; 81(5): 1073–1086. doi: 10.1016/ j.gie.2015.02.023.

23. Herve J, Wahlen CH, Schaeken S et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 2005; 15(6): 864–870. doi: 10.1381/ 09608920 54222894.

24. Marinos G, Eliades C, Muthusamy VR et al. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3-and 6-month study. Surg Obes Relat Dis 2014; 10(5): 929–934. doi: 10.1016/ j.soard.2014.03.005.

25. Sauer N, Rösch T, Pezold J et al. A new endoscopically implantable device (SatiSphere) for treatment of obesity-efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg 2013; 23(11): 1727–1733. doi: 10.1007/ s11695-013-1005-0.

26. Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc 2019; 90(5): 770–780. doi: 10.1016/ j.gie.2019.06.013.

27. López-Nava G, Galvão MP, Bautista-Castano I et al. Endoscopic sleeve gastroplasty for obesity treatment: two years of experience. Arq Bras Cir Dig 2017; 30(1): 18–20. doi: 10.1590/ 0102-6720201700010006.

28. Huberty V, Boskoski I, Bove V et al. Endoscopic sutured gastroplasty in addition to lifestyle modification: short-term efficacy in a controlled randomised trial. Gut 2020. doi: 10.1136/ gutjnl-2020-322026.

29. López-Nava G, Bautista-Castano I, Jimenez A et al. The primary obesity surgery endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2015; 11(4): 861–865. doi: 10.1016/ j.soard.2014.09.026.

30. Espinós JC, Turró R, Mata M, et al. Early experience with the Incisionless Operating Platform (IOP) for the treatment of obesity : the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes Surg 2013; 23(9): 1375-1383. doi: 10.1007/s11695-013-0937-8.

31. Sullivan S, Swain JM, Woodman G et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring) 2017; 25(2): 294–301. doi: 10.1002/oby.21702.

32. López-Nava G, Asokkumar R, Arau RT et al. Modified primary obesity surgery endoluminal (POSE-2) procedure for the treatment of obesity. VideoGIE 2020; 5(3): 91–93. doi: 10.1016/j.vgie.2019.11.010.

33. Kumar N. Endoscopic therapy for weight loss: gastroplasty, duodenal sleeves, intragastric balloons, and aspiration. World J Gastrointest Endosc 2015; 7(9): 847–859. doi: 10.4253/wjge.v7.i9.847.

34. Devière J, Valdes GO, Herrera LC et al. Safety, feasibility and weight loss after transoral gastroplasty: first human multicenter study. Surg Endosc 2008; 22(3): 589–598. doi: 10.1007/s00464-007-9662-5.

35. Moreno C, Closset J, Dugardeyn S et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. Endoscopy 2008; 40(5): 406–413. doi: 10.1055/s-2007-995748.

36. Koehestanie P, de Jonge C, Berends FJ et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 2014; 260(6): 984–992. doi: 10.1097/SLA.0000000000000794.

37. Beneš M, Hucl T, Drastich P et al. The duodenal-jejunal bypass liner (EndoBarrier®) for the treatment of type 2 diabetes mellitus in obese patients – efficacy and factors predicting optimal effects. Gastroent Hepatol 2016; 70(6): 491–499. doi:10.14735/amgh2016csgh.info15.

38. Forner PM, Ramacciotti T, Farey JE et al. Safety and effectiveness of an endoscopically placed duodenal-jejunal bypass device (EndoBarrierA®): outcomes in 114 patients. Obes Surg 2017; 27(12): 3306–3313. doi: 10.1007/s11695-017-2939-4.

39. Sandler BJ, Rumbaut R, Swain CP et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 2015; 29(11): 3298–3303. doi: 10.1007/s00464-015-4081-5.

40. Norén E, Forssell H. Aspiration therapy for obesity; a safe and effective treatment. BMC Obes 2016; 3: 56. doi: 10.1186/s40608-016-0134-0.

41. Thompson CC, Dayyeh BK, Kushnir V et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis 2019; 15(8): 1348–1354. doi: 10.1016/j.soard.2019.04.026.

42. Zhang Y, Du S, Fang L et al. Retrograde gastric electrical stimulation suppresses calorie intake in obese subjects. Obesity (Silver Spring) 2014; 22(6): 1447–1451. doi: 10.1002/oby.20664.

43. Bohdjalian A, Ludvik B, Guerci B et al. Improvement in glycemic control by gastric electrical stimulation (TANTALUS) in overweight subjects with type 2 diabetes. Surg Endosc 2009; 23(9): 1955–1960. doi: 10.1007/s00464-008-0222-4.

44. Cha R, Marescaux J, Diana M. Updates on gastric electrical stimulation to treat obesity: systematic review and future perspectives. World J Gastrointest Endosc 2014; 6(9): 419–431. doi: 10.4253/wjge.v6.i9.419.

45. Gniuli D, Calcagno A, Libera LD et al. High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP) – expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia 2010; 53(10): 2233–2240. doi: 10.1007/s00125-010-1830-9.

46. Rajagopalan H, Cherrington AD, Thompson CC et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 2016; 39(12): 2254–2261. doi: 10.2337/dc16-0383.

47. van Baar AC, Holleman F, Crenier L et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut 2020; 69(2): 295–303. doi: 10.1136/gutjnl-2019-318349.

48. Hu B, Ye LS. Endoscopic applications of magnets for the treatment of gastrointestinal diseases. World J Gastrointest Endosc 2019; 11(12): 548–560. doi: 10.4253/wjge.v11.i12.548.

49. Marrache MK, Itani MI, Farha J et al. Endoscopic gastrointestinal anastomosis: a review of established techniques. Gastrointest Endosc 2021; 93(1): 34–46. doi: 10.1016/j.gie.2020.06.057.

50. Machytka E, Bužga M, Zonca P et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc 2017; 86(5): 904–912. doi: 10.1016/j.gie.2017.07.009.

51. Bang CS, Baik GH, Shin IS et al. Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression. Gastrointest Endosc 2015; 81(5): 1141–1149. e1–e7. doi: 10.1016/j.gie.2014.12.025.

52. Tremmel M, Gerdtham UG, Nilsson PM et al. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health 2017; 14(4): 435. doi: 10.3390/ijerph14040435.